Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Status: | Completed |
---|---|
Conditions: | Blood Cancer, Women's Studies, Hematology |
Therapuetic Areas: | Hematology, Oncology, Reproductive |
Healthy: | No |
Age Range: | 18 - 60 |
Updated: | 12/20/2018 |
Start Date: | February 12, 2013 |
End Date: | June 15, 2017 |
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)
This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or
idarubicin and cytarabine with or without vorinostat to see how well they work in treating
younger patients with previously untreated acute myeloid leukemia. Drugs used in
chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat,
work in different ways to stop the growth of cancer cells, either by killing the cells,
stopping them from dividing, or by stopping from spreading. Giving more than one drug
(combination chemotherapy) and giving the drugs in different doses and in different
combinations may kill more cancer cells. It is not yet known which combination chemotherapy
is more effective in treating acute myeloid leukemia.
idarubicin and cytarabine with or without vorinostat to see how well they work in treating
younger patients with previously untreated acute myeloid leukemia. Drugs used in
chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat,
work in different ways to stop the growth of cancer cells, either by killing the cells,
stopping them from dividing, or by stopping from spreading. Giving more than one drug
(combination chemotherapy) and giving the drugs in different doses and in different
combinations may kill more cancer cells. It is not yet known which combination chemotherapy
is more effective in treating acute myeloid leukemia.
PRIMARY OBJECTIVES:
I. To compare event-free survival (EFS) between patients with acute myeloid leukemia (AML)
who receive standard 7+3 (cytarabine and daunorubicin hydrochloride) or idarubicin and
high-dose cytarabine (IA) to patients who receive IA + vorinostat. (Chemotherapy) II. To
determine whether it is possible to get 60% or more of adults with high-risk AML (by
cytogenetics) in first complete remission (CR1) to allogeneic hematopoietic cell
transplantation (HCT). (Transplant)
SECONDARY OBJECTIVES:
I. To estimate the frequency and severity of toxicities of the three regimens in this patient
population. (Chemotherapy) II. To estimate disease-free survival (DFS) among patients who
receive transplant. (Transplant) III. To compare event-free survival (EFS) between patients
who receive standard 7 + 3 to patients who receive IA. (Chemotherapy) IV. To estimate the
prevalence of the mutations nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1),
isocitrate dehydrogenase 1 (NADP+), soluble (IDH1), isocitrate dehydrogenase 2 (NADP+),
mitochondrial (IDH2), tet methylcytosine dioxygenase 2 (TET2) and deoxyribonucleic acid (DNA)
(cytosine-5-)-methyltransferase 3 alpha (DNMT3A) and the cytogenetic risk distribution of
patients on this study and to evaluate the association between these and overall survival
(OS), event-free survival (EFS), disease-free survival (DFS), and complete remission rate.
(Chemotherapy/Translational Medicine) V. To compare the complete response rate, disease-free
survival (DFS), and overall survival (OS) between patients who receive standard 7+3 therapy
or IA to patients who receive IA + vorinostat. (Chemotherapy)
TERTIARY OBJECTIVES:
I. Future planned studies will include testing of histone H3 acetylation, induction of gamma
H2A histone family, member X (H2AX), analysis of reactive oxygen species (ROS) resistance and
DNA methylation profiles. (Chemotherapy/Translational Medicine)
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
INDUCTION/RE-INDUCTION:
ARM I: Patients receive standard dose cytarabine intravenously (IV) continuously on days 1-7
and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive
re-induction treatment beginning on day 15. Patients achieving complete remission (CR) or
complete remission with incomplete platelet recover (CRi) may proceed to allogeneic
hematopoietic stem cell transplant (HSCT) or to consolidation therapy.
ARM II: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV
over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment
beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to
consolidation therapy.
ARM III: Patients receive vorinostat orally (PO) thrice daily (TID) on days 1-3, high-dose
cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6.
Patients with residual blasts may receive re-induction treatment beginning on day 28.
Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.
(Permanently closed to accrual, effective 6/2/2015) Patient previously randomized to Arm III
may continue treatment without vorinostat.
CONSOLIDATION:
ARM I: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.
ARM II: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15
minutes on days 1-2.
ARM III: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days
4-6, and idarubicin IV over 15 minutes on days 4-5. (Permanently closed to accrual, effective
6/2/2015) Patient previously randomized to Arm III may continue treatment with or without
vorinostat.
In all arms, treatment repeats every 28 days for 4 courses or until transplant in the absence
of disease progression or unacceptable toxicity.
TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or
consolidation therapy.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 6 months for 2 years, and then annually for 2 years.
I. To compare event-free survival (EFS) between patients with acute myeloid leukemia (AML)
who receive standard 7+3 (cytarabine and daunorubicin hydrochloride) or idarubicin and
high-dose cytarabine (IA) to patients who receive IA + vorinostat. (Chemotherapy) II. To
determine whether it is possible to get 60% or more of adults with high-risk AML (by
cytogenetics) in first complete remission (CR1) to allogeneic hematopoietic cell
transplantation (HCT). (Transplant)
SECONDARY OBJECTIVES:
I. To estimate the frequency and severity of toxicities of the three regimens in this patient
population. (Chemotherapy) II. To estimate disease-free survival (DFS) among patients who
receive transplant. (Transplant) III. To compare event-free survival (EFS) between patients
who receive standard 7 + 3 to patients who receive IA. (Chemotherapy) IV. To estimate the
prevalence of the mutations nucleophosmin (nucleolar phosphoprotein B23, numatrin) (NPM1),
isocitrate dehydrogenase 1 (NADP+), soluble (IDH1), isocitrate dehydrogenase 2 (NADP+),
mitochondrial (IDH2), tet methylcytosine dioxygenase 2 (TET2) and deoxyribonucleic acid (DNA)
(cytosine-5-)-methyltransferase 3 alpha (DNMT3A) and the cytogenetic risk distribution of
patients on this study and to evaluate the association between these and overall survival
(OS), event-free survival (EFS), disease-free survival (DFS), and complete remission rate.
(Chemotherapy/Translational Medicine) V. To compare the complete response rate, disease-free
survival (DFS), and overall survival (OS) between patients who receive standard 7+3 therapy
or IA to patients who receive IA + vorinostat. (Chemotherapy)
TERTIARY OBJECTIVES:
I. Future planned studies will include testing of histone H3 acetylation, induction of gamma
H2A histone family, member X (H2AX), analysis of reactive oxygen species (ROS) resistance and
DNA methylation profiles. (Chemotherapy/Translational Medicine)
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
INDUCTION/RE-INDUCTION:
ARM I: Patients receive standard dose cytarabine intravenously (IV) continuously on days 1-7
and daunorubicin hydrochloride IV on days 1-3. Patients with residual blasts may receive
re-induction treatment beginning on day 15. Patients achieving complete remission (CR) or
complete remission with incomplete platelet recover (CRi) may proceed to allogeneic
hematopoietic stem cell transplant (HSCT) or to consolidation therapy.
ARM II: Patients receive high dose cytarabine IV continuously on days 1-4 and idarubicin IV
over 15 minutes on days 1-3. Patients with residual blasts may receive re-induction treatment
beginning on day 28. Patients achieving CR or CRi may proceed to allogeneic HSCT or to
consolidation therapy.
ARM III: Patients receive vorinostat orally (PO) thrice daily (TID) on days 1-3, high-dose
cytarabine IV continuously on days 4-7, and idarubicin IV over 15 minutes on days 4-6.
Patients with residual blasts may receive re-induction treatment beginning on day 28.
Patients achieving CR or CRi may proceed to allogeneic HSCT or to consolidation therapy.
(Permanently closed to accrual, effective 6/2/2015) Patient previously randomized to Arm III
may continue treatment without vorinostat.
CONSOLIDATION:
ARM I: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5.
ARM II: Patients receive cytarabine IV continuously on days 1-3 and idarubicin IV over 15
minutes on days 1-2.
ARM III: Patients receive vorinostat PO TID on days 1-3, cytarabine IV continuously on days
4-6, and idarubicin IV over 15 minutes on days 4-5. (Permanently closed to accrual, effective
6/2/2015) Patient previously randomized to Arm III may continue treatment with or without
vorinostat.
In all arms, treatment repeats every 28 days for 4 courses or until transplant in the absence
of disease progression or unacceptable toxicity.
TRANSPLANT: Patients may undergo an allogeneic transplant after induction therapy or
consolidation therapy.
After completion of study treatment, patients are followed up every 3 months for 1 year,
every 6 months for 2 years, and then annually for 2 years.
Inclusion Criteria:
- STEP 1 - INDUCTION/RE-INDUCTION
- Patients must have morphologically confirmed newly diagnosed acute myelogenous
leukemia (AML) with blood or bone marrow disease; patients with only extramedullary
disease in the absence of bone marrow or blood involvement are not eligible; note:
this protocol uses World Health Organization (WHO) diagnostic criteria for AML;
patients with acute promyelocytic leukemia (APL, French-American-British [FAB], M3) or
blastic transformation of chronic myelogenous leukemia (CML) are not eligible;
patients with known core binding factor (CBF) or fms-like tyrosine kinase 3 (FLT3)
related leukemias are eligible for this study, but should preferentially be placed on
National Cancer Institute (NCI)-sponsored protocols specific for these subtypes, if
available
- Patients must have diagnostic/pre-treatment specimens obtained within 28 days prior to
registration submitted for cytogenetic (and fluorescent in situ hybridization [FISH]
if possible) analysis to determine risk status; high risk classification will be
defined as del(5q)/-5, del(7q)/-7, abn3q26 [inv(3)/t(3;3)], 11q23 rearrangement
[except t(9;11)], 17p-, t(6;9), t(9;22), complex (at least 3 unrelated abnormalities
[abn]), and monosomal karyotype (either loss of two different chromosomes or loss of
one chromosome along with a structural chromosome abnormality other than add, ring and
mar); karyograms and cytogenetics/FISH analysis reports must be submitted for
discipline review
- Patients must be chemo-naïve, i.e., not have received any prior induction chemotherapy
for AML or myelodysplastic syndrome (MDS); temporary prior measures such as apheresis
or hydroxyurea are allowed; prior anthracycline therapy is allowed, but must not
exceed a dose of 200 mg/m^2 daunorubicin or equivalent; prior all-trans retinoic acid
(ATRA) for suspected APL is allowed; prior methotrexate for central nervous system
(CNS) involvement is allowed; patients with prior history of MDS must not have
received azacitidine, decitabine, lenalidomide or vorinostat
- Patients must have peripheral blood and bone marrow aspirate specimens obtained within
28 days prior to registration submitted for translational medicine; with patient
consent, residuals will be banked for future research
- Patients must have Zubrod performance status =< 3
- Patients must have either echocardiogram (ECHO) or multi gated acquisition scan (MUGA)
with ejection fraction >= 45% within 28 days prior to registration
- Patients must not have prolonged corrected QT (QTc) interval (> 500 msec) determined
by electrocardiogram (EKG) within 28 days prior to registration
- Patients must not have cardiac disease defined as: New York Heart Association (NYHA) >
class II; patients must not have unstable angina (angina symptoms at rest) or new
onset angina (began within the last 3 months) or myocardial infarction within the past
6 months
- Patients must not have any coexisting medical condition that is likely to interfere
with study procedures or results, and must be reasonable candidates for intensive
chemotherapy, in the opinion of their treating physicians
- Patients who are known to be human immunodeficiency virus (HIV) positive (+) are
eligible providing they meet all of the following additional criteria within 28 days
prior to registration:
- Cluster of differentiation (CD) 4 cells >= 500/mm^3
- Viral load < 50 copies of HIV messenger ribonucleic acid (mRNA)/mm^3 if on
combination antiretroviral therapy (cART) or < 25,000 copies of HIV mRNA if not
on cART
- No zidovudine or stavudine as part of cART; patients who are HIV+ and do not meet
all of these criteria are not eligible for this study
- Patients with known hepatitis B or hepatitis C infection may be eligible providing
they have viral load < 800,000 IU/mL within 28 days prior to registration
- Patients must be able to take oral medications
- Patients must have a history and physical examination obtained within 28 days prior to
registration
- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures
- Prior malignancy is allowed providing it does not require concurrent therapy;
exception: active hormonal therapy is allowed
- Patients must not be receiving valproic acid
- All patients must be informed of the investigational nature of this study; patients or
a legally authorized representative must sign and give written informed consent in
accordance with institutional and federal guidelines
- As part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system
- STEP 2 - CONSOLIDATION
- Patients may be registered for consolidation provided that they were eligible for the
initial induction/re-induction registration and satisfy the following additional
criteria:
- Patients must have achieved morphologic remission (complete remission [CR] or
complete remission with incomplete blood count recover [CRi]) after completion of
induction or re-induction therapy; patient must remain in remission until
beginning consolidation and this must be documented by bone marrow and peripheral
blood examination within 28 days prior to registration to Step 2
- All non-hematologic treatment related toxicities that are deemed clinically
significant by the treating physician must have resolved to =< grade 2
- Patients must not have received allogeneic stem cell transplant
We found this trial at
442
sites
Hematology Oncology Associates of Illinois At Hematology Oncology Associates of Illinois, our goal is to...
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Click here to add this to my saved trials
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Click here to add this to my saved trials
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
Click here to add this to my saved trials
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
Click here to add this to my saved trials
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
Spokane, Washington 99202
(509) 228-1000
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
American Fork, Utah 84003
Click here to add this to my saved trials
McFarland Clinic PC-William R Bliss Cancer Center The William R. Bliss Cancer Center at Mary...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
Summa Barberton Hospital Summa Barberton Hospital is a full member of Summa Health System and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
1501 North Oakland Drive
Bolivar, Missouri 65613
Bolivar, Missouri 65613
417-326-7200
Central Care Cancer Center at Carrie J. Babb Cancer Center Cancer treatment often requires a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Massachusetts General Hospital Cancer Center An integral part of one of the world
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
Click here to add this to my saved trials
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
Click here to add this to my saved trials
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
Click here to add this to my saved trials
Click here to add this to my saved trials
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
Click here to add this to my saved trials
Rocky Mountain Oncology Rocky Mountain Oncology Center is a spacious, comfortable, state-of-the-art 19,000 square foot...
Click here to add this to my saved trials
Sandra L. Maxwell Cancer Center The Huntsman-Intermountain Cancer Center at Valley View Medical Center in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
Chicago, Illinois 60637
1-773-702-6180
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials